The copper chaperone for the superoxide dismutase (CCS) gene is necessary for expression of an active, copper-bound form of superoxide dismutase (SOD1) in vivo in spite of the high affinity of SOD1 for copper (dissociation constant ϭ 6 fM) and the high intracellular concentrations of both SOD1 (10 M in yeast) and copper (70 M in yeast). In vitro studies demonstrated that purified Cu(I)-yCCS protein is sufficient for direct copper activation of apo-ySOD1 but is necessary only when the concentration of free copper ions ([Cu] free ) is strictly limited. Moreover, the physiological requirement for yCCS in vivo was readily bypassed by elevated copper concentrations and abrogation of intracellular copper-scavenging systems such as the metallothioneins. This metallochaperone protein activates the target enzyme through direct insertion of the copper cofactor and apparently functions to protect the metal ion from binding to intracellular copper scavengers. These results indicate that intracellular [Cu] free is limited to less than one free copper ion per cell and suggest that a pool of free copper ions is not used in physiological activation of metalloenzymes.
The copper chaperone for the superoxide dismutase (CCS) gene is necessary for expression of an active, copper-bound form of superoxide dismutase (SOD1) in vivo in spite of the high affinity of SOD1 for copper (dissociation constant ϭ 6 fM) and the high intracellular concentrations of both SOD1 (10 M in yeast) and copper (70 M in yeast). In vitro studies demonstrated that purified Cu(I)-yCCS protein is sufficient for direct copper activation of apo-ySOD1 but is necessary only when the concentration of free copper ions ([Cu] free ) is strictly limited. Moreover, the physiological requirement for yCCS in vivo was readily bypassed by elevated copper concentrations and abrogation of intracellular copper-scavenging systems such as the metallothioneins. This metallochaperone protein activates the target enzyme through direct insertion of the copper cofactor and apparently functions to protect the metal ion from binding to intracellular copper scavengers. These results indicate that intracellular [Cu] free is limited to less than one free copper ion per cell and suggest that a pool of free copper ions is not used in physiological activation of metalloenzymes.
Metalloproteins such as the antioxidant enzyme Cu,Zn-superoxide dismutase (SOD1) (1, 2) are generally assumed to acquire the essential cofactors by passive diffusion, although recent studies indicate that more complex mechanisms are involved. A network of copper-trafficking genes including ATX1 and LYS7 of Saccharomyces cerevisiae and their mammalian homologs are required for copper incorporation of proteins in vivo (3) (4) (5) (6) (7) . The LYS7 gene, which encodes the yeast copper chaperone for superoxide dismutase (yCCS) (4) , is essential for expression of the functional, copper-bound form of yeast SOD1 (ySOD1) in vivo. Possible roles for yCCS in activation of ySOD1 include insertion of copper, stabilization of protein-folding intermediates, enhancement of protein stability, or modulation of intracellular copper availability in concert with other cellular factors. We found that yCCS directly inserts copper into the target enzyme and that this metallochaperone is necessary only if the ambient free copper concentration is exceedingly low. These results lead to the conclusion that the intracellular milieu has an extraordinary overcapacity for chelation of copper. In contrast to the emerging picture of energydependent iron uptake (8), we anticipate that this chelation capacity leads to a substantial driving force for copper passage into the cell.
The requirement for yCCS in vivo was first examined by measuring the intracellular concentrations of copper, yCCS protein, and the ySOD1 target enzyme (9-12). In agreement with previous studies (4), we found that the absence of yCCS did not decrease the total number of ySOD1 molecules yet substantially reduced the ratio of the active, copper-bound ySOD1 to the inactive apo form of the enzyme (Table 1 ). In addition, the total number of copper atoms in these strains was similar regardless of the presence of yCCS or ySOD1 ( Table 1 ), demonstrating that despite the loss of either abundant copper-binding protein, the number of copper ions per cell remains constant. Thus, there is no apparent role for yCCS in modulation of copper uptake or target enzyme stability.
To determine if this metallochaperone is sufficient for direct activation of the metaldepleted ySOD1 (apo-ySOD1), we expressed yCCS in Escherichia coli, purified it to homogeneity (Fig. 1A) (13) , and incubated the copper-loaded form with purified samples of denatured apo-ySOD1 (14, 15). Yeast SOD1 enzyme was acid denatured and lyophilized after metal removal and was then treated with Cu(I)-yCCS or CU(I)-GSH copper donors (Fig. 1, B and C). The glutathione (GSH) complex of Cu(I), a compound previously invoked as a possible physiological Cu donor (16), was used as a control. After incubation with copper donors, the resulting ySOD1 activity was assessed by the standard kinetic assay with cytochrome c (17). Apo-ySOD1 was activated upon treatment with either Cu(I)-yCCS or Cu(I)-GSH. Copper in either the cuprous [Cu(CH 3 CN) 4 PF 6 ] or cupric (CuSO 4 ) oxidation state also activated apoySOD1 under similar conditions. The yCCS metallochaperone is thus unnecessary for in vitro ySOD1 activation if a sufficient pool of copper is accessible to the apo-enzyme.
In contrast, the in vivo measurements indicated that ySOD1 is inactive in the absence of yCCS, even though total cellular copper remains at normal concentrations ( Samples of these same reconstitution mixtures were also assayed on native polyacrylamide gels stained for SOD activity with nitroblue tetrazolium (NBT) (Fig. 1C) . The resulting SOD activity bands confirmed the previous conclusion and established that the bulk superoxide disproportionation activity detected in the kinetic assays arose from ySOD1 enzyme rather than other adventitious reactions. Control samples of Cu-yCCS or Cu-GSH that lacked apo-yCCS also displayed no SOD activity bands comparable to holo-ySOD1.
The in vitro results indicate that yCCS alone is sufficient for activation of the target enzyme. Furthermore, the metal insertion event apparently proceeds with direct transfer of the copper ion from yCCS to the ySOD1 target enzyme. The inability of Cu(I)-GSH to activate ySOD1 in the presence of BCS (Fig.  1B) precludes an indirect transfer mechanism in which copper is first released from yCCS into solution and subsequently binds to apo-SOD. Copper ions that may dissociate from yCCS or GSH are rapidly sequestered by the BCS competitor (present in 20-fold excess over the copper donor molecule), resulting in a complex that is incapable of donating copper to ySOD1 apo-enzyme.
The biochemical activation data also suggest that the strict genetic requirement for yCCS will only be manifested when the cytoplasmic concentration of free copper is negligible. To test this proposition in vivo, we increased cytoplasmic concentrations of available copper by two means: exposure of cells to elevated copper concentrations in the growth medium ([Cu] medium ) or elimination of cytoplasmic copper-sequestering proteins.
Elevation of [Cu] medium from submicromolar concentrations to 5 mM failed to activate ySOD1 in cells lacking the yCCS metallochaperone. As [Cu] medium was further increased to toxic amounts, however, the total number of copper atoms per cell increased by 100-fold and ySOD1 activity became apparent in native gels assays of cytoplasmic extracts ( Fig. 2A) . Thus, a key limitation to ySOD1 activity is the low availability of copper within the cell. Given that cells lacking the metallochaperone have similar amounts of copper and ySOD1 (Table 1) to wild-type cells, it is clear that the copper must be bound tightly at other sites that are inaccessible to apo-ySOD1. Candidates for such copper-sequestration sites include the yeast metallothionein isoforms encoded by CUP1 and CRS5 (19, 20) .
The role of yeast metallothioneins in restricting intracellular [Cu] free was evaluated in yeast strains with deleted CUP1 and CRS5 genes (designated MT Ϫ ) that also lacked yCCS (9). In the absence of yCCS, ySOD1 activity in these strains was dependent on the dose of copper provided in the medium (Fig.  2B ). ySOD1 activity became apparent at [Cu] medium ϭ 0.5 mM, at which point cellular copper accumulation increased by 10-fold. This represents an order of magnitude less than the total cellular copper or [Cu] medium required to activate a comparable amount of ySOD1 in the yeast strain expressing MTs (Fig. 2A ). These results demonstrate that yeast metallothioneins limit copper availability to ySOD1. Because additional copper must still be added to the medium to observe SOD activity, MTs must provide only part of Table 1 and show typical variations in the extent of copper accumulation. Table 1 . Amounts of copper and SOD1 per cell and resistance to copper toxicity in various yeast strains (9). Amounts of copper are reported in atoms per cell as determined by elemental analysis of whole cells (10). Total SOD1 and yCCS were determined by protein immunoblotting and are given as the number of molecules of monomers per cell (11). Active SOD1 is given as an upper limit of active SOD1 monomers per cell as determined by gel analysis of SOD1 activity (12). Mean inhibitory concentration (MIC) is the concentration of copper sulfate required to inhibit yeast growth in a synthetic dextrose minimal medium (27) the copper-chelation capacity in the cell. Furthermore, the fact that ySOD1 can be activated by copper in vivo in the absence of yCCS (Fig. 2) argues against an essential role for yCCS in activation of apo-ySOD1 through protein-folding pathways. We conclude that the yCCS molecule specifically delivers ϳ15% of the total cellular copper pool to saturate the ySOD1 pool ( Ϫ10 M. It is unclear whether the intracellular copperySOD1 system is at equilibrium; however, the rate of copper binding to ySOD1 in vitro is quite rapid (22). Using a kinetic model (22), we arrived at the same conclusion: There is less than one free copper atom per cell under normal growth conditions. Given the high intracellular capacity for copper binding, we anticipate that kinetic aspects of specific metallochaperone interactions will control the extent of copper transfer to target versus nontarget molecules.
The results indicate that intracellular copper availability is extraordinarily restricted. The extensive chelation capacity allows too few free copper ions to become available to saturate the 60,000 molecules of SOD1 within the typical life-span of a yeast cell. This provides a context for understanding the driving force for metal uptake in general (8) but more specifically underscores the physiological requirement for metallochaperones: Copper-dependent enzymes require accessory factors to compete with chelators and processes that sequester essentially all intracellular free copper. In this way, the metallochaperones protect copper ions. It has been suggested that copper chaperones protect cells against copper toxicity (3, 5) . We do observe some protective effects of yCCS with respect to elevated [Cu] medium (MIC values, Table 1 ), although this protection likely results from insertion of metal into ySOD1 (itself a cellular buffer for copper) rather than from sequestration by yCCS (23) . The central function of this metallochaperone is to directly insert the cofactor into the target enzyme, thus converting the latter from an inactive to an active state. In this sense, the function of the yCCS protein is analogous to that of the molecular chaperones, although it is unclear at this time whether yCCS also increases the efficiency of ySOD1 folding. These issues may be important in understanding the pathological features of the large number of known mutations in human SOD1 that lead to amyotrophic lateral sclerosis (24, 25) .
Note added in proof: Since submission of this paper, Lyons et al. (31) have proposed that in the absence of yCCS, intracellular SOD1 exists with one zinc ion bound per SOD dimer. This is compatible with our results, which do not address whether zinc is bound by SOD1 before or after copper insertion by yCCS. 9. The isogenic wild-type SY1699 and lys7 null SY2950 strains were described [ J. Horecka, P. to remove trace metals. Yeast cells were dried overnight at 75°to 80°C until no further change in mass was observed, dissolved in concentrated nitric acid (300 to 500 l), and heated at 80°C for 30 min.
Parallel control experiments examined background amounts of copper in the materials used. Elemental analysis of hydrolyzed cells was measured by inductively coupled plasma-atomic emission spectroscopy (AtomScan ICP-AES). 11. The amounts of ySOD1 and yCCS were measured in whole-cell extracts (26) prepared from cells grown to an early logarithmic phase in enriched yeast extract, peptone, and dextrose (YPD) medium (27) . Protein immunoblotting was done with 1 to 200 ng of purified yCCS or purified ySOD1 as standards (vida infra) and detected with polyclonal rabbit antisera to yCCS (Biodesign International, Kennebunk, ME) or yeast SOD1. We observed that 15 g of the extract protein (corresponding to 5.35 ϫ 10 6 yeast cells on the basis of our empirical estimations of 2.8 pg of protein yield per cell for strain SY1699) contained 9 to 10.5 ng of SOD1 or 2 to 3 ng of yCCS, corresponding to about 6 ϫ 10 4 and 1 ϫ 10 4 molecules per cell, respectively. 12. To determine the number of copper-loaded SOD1 molecules per cell, crude yeast extract protein [prepared as described (11) and concentrated as needed] was subjected to a nondenaturing gel-NBT assay for SOD1 activity (28) . Purified ySOD1 (14) was used as a standard and was shown to be fully loaded with copper by elemental analysis. The lower limit of detection was 2 ng (7.6 ϫ 10 10 monomers) of copper-loaded SOD1. SOD1 from wild-type strains exhibited 50 to 100% of the activity of the ySOD1 standard, whereas no SOD1 activity could be detected in lys7 null strains, even in samples containing 3.0 ϫ 10 8 cells. 13. The LYS7 gene was amplified by polymerase chain reaction, subcloned into pET11d (Novagen), and confirmed by restriction mapping and DNA sequencing. In this process, the second amino acid was altered from Thr to Ala. Constructs were transformed into E. coli strain BL21(DE3) for overexpression. yCCS was purified by chromatography on anion exchange, cation exchange, and size exclusion resins. Electrospray mass spectrometry (ESI-MS) gave a single peak at mass-to-charge ratio m/z ϭ 27,169 daltons, which agrees with the predicted molecular mass of the full-length protein minus the NH 2 -terminal methionine. Protein concentrations were determined with a calibrated Bradford (Bio-Rad) curve with immunoglobulin G as the standard. A correction factor of 2.28 was necessary to correct the overestimation of yCCS by the Bradford method as determined by amino acid hydrolysis. The Cu(I) complex of yCCS was obtained by incubation of purified yCCS (100 M) in 50 mM tris (pH 8.0), 10 mM dithiothreitol (DT T), and 200 mM NaCl with 1 molar equivalent of Cu(I)(CH 3 CN) 4 PF 6 complex for 2 hours. Cu(I)-yCCS was then washed with repeated dialysis with the same tris/DT T/NaCl buffer, followed by dialysis exchanges against 50 mM tris (pH 8.0) alone to remove DT T and NaCl. All stages of the Cu(I)-yCCS complexation procedure were performed in an anaerobic glove box. Copper analysis by ICP-AES and calibrated Bradford protein assay revealed a 1.1:1 Cu(I)-yCCS complex. 14. Yeast SOD1 protein for activation assays was expressed in E. coli BL21(DE3) transformed with ySOD1-pET3d and isolated by anion exchange chromatography. Isolated enzyme was then denatured and demetallated by treatment with 0.1 M DT T, 10 mM EDTA, 1 mM BCS, 15% CH 3 CN, and 0.1% trifluoroacetic acid, followed by further purification by reverse-phase high-performance liquid chromatography through a C4 Vydac 214TP54 column. The ySOD1 protein fractions were combined, dried under vacuum, and applied directly to the in vitro activation assays described below. A mass of 15,722.5 daltons determined by ESI-MS confirmed the identity of the purified ySOD1 monomer (theoretical mass of 15,723 daltons). Holo-ySOD1 for positive controls was isolated from baker's yeast cake by the chloroform-ethanol extraction procedure as described (29) . 15. All samples for activation assays contained 1.8 M apo-ySOD1, 1 mM GSH, and 20 M ZnSO 4 in 50 mM potassium phosphate buffer (pH 7.8). Where indicated in Fig. 1 , specific reaction mixtures included either 10 M Cu(I)-yCCS or 10 M Cu(I)(CH 3 CN) 4 PF 6 and 0 or 200 M BCS. The standard cytochrome c-xanthine oxidase assay for SOD activity (17) was executed in triplicate for each reaction mixture, and 1 mM EDTA was included in the assay buffer. SOD activity staining of native polyacrylamide gel electrophoresis (PAGE) gels with NBT was done as described (28 Over the past decade, genetically engineered mouse models of cancer have increasingly been used in studies on mechanisms of carcinogenesis. One strength of these models is that cancers arise from normal cells in their natural tissue microenvironments and progress through multiple stages, as does human cancer (1). Such models of organ-specific cancer also present opportunities for development not only of cancer therapies but also of preventative strategies that block the progression of premalignant lesions into tumors. The RIP1-Tag2 transgenic mouse model of pancreatic islet carcinogenesis serves as a general prototype of the pathways, parameters, and molecular mechanisms of multistage tumorigenesis. The pathway through which normal insulin-producing ␤ cells of the pancreatic islets are converted into islet cell carcinomas under the influence of the SV40 T antigen (Tag) is increasingly well understood (2, 3) . Briefly, in the RIP1-Tag2 line, the following stages arise sequentially over the 13.5-week average lifetime of these mice. Normal islets (initially 100% of the ϳ400 islets per pancreas) express the Tag oncogene and yet are morphologically asymptomatic until 3 to 4 weeks of age. Hyperplastic islets then begin to appear stochastically (increasing to 50% of the islets by 10 weeks), displaying ␤-cell hyperproliferation and features of dysplasia and carcinoma in situ. Angiogenic islets (8 to 12%) arise from hyperplastic/dysplastic islets by switching on angiogenesis in the normally quiescent islet capillaries (3). This switch is characterized by endothelial proliferation, vascular dilation, and microhemorrhaging. Solid tumors (ϳ3% of the islets) emerge at 10 weeks as small encapsulated tumors (adenomas) that progress by 12 to 13 weeks into large adenomas and (less frequently) invasive carcinomas, both of which are intensely vascularized by dilated hemorrhagic vessels.
In earlier work, we showed that a mixture of three angiogenesis inhibitors (AGM-1470, minocycline, and alpha interferon) could inhibit tumor growth in the RIP-Tag model (4) . These data supported other preclinical data from subcutaneous transplant models (5-7). Encouraged by the result, we designed the present study to assess the effects of four diverse angiogenesis inhibitors when applied to RIP1-Tag2 mice at three distinct stages of pancreatic islet carcinogenesis. Figure 1 illustrates the experimental design, which had three branches: (i) early treatment at the hyperplastic stage to block the angiogenic switch before the initial formation of solid tumors (prevention trial), (ii) treatment of mice bearing small (asymptomatic) solid tumors to determine whether their expansive growth and progression to deleterious stages could be stopped (intervention trial), and (iii) treatment of mice with substantial tumor burden and near death to ascertain whether these agents could induce tumor regression (regression trial). We evaluated four angiogenesis inhibitors (8) (Tables 1 and 2 ): AGM-1470 (TNP470), BB-94 (batimastat), angiostatin, and endostatin, as well as the combination of angiostatin and endostatin. AGM-1470 (TNP470) is a small molecule inhibitor of endothelial cell proliferation (9) that is thought to act by inhibiting an intracellular enzyme, methionylaminopeptidase-2 (9). BB-94 (batimastat) is a broad-spectrum inhibitor of matrix metalloproteinases (10), which are involved in the remodeling of extracellular matrix and capillary basement membranes during angiogenesis (11). An-
